Panbela Therapeutics company info

What does Panbela Therapeutics do?
Panbela Therapeutics (NASDAQ:PBLA) focuses on developing innovative therapies for patients battling cancer. With a strong commitment to scientific excellence and patient care, Panbela is advancing a diverse portfolio of projects aimed at addressing some of the most challenging types of cancer. Its objective is to pioneer treatments that not only extend life but also improve its quality for those facing cancer diagnoses. By leveraging cutting-edge research and development, Panbela is dedicated to bringing novel oncology therapies from the laboratory to the clinic. The company's approach combines a deep understanding of cancer biology with advanced pharmacological techniques to create targeted treatments intended to manage and overcome cancer's complexities.
Panbela Therapeutics company media
Company Snapshot

Is Panbela Therapeutics a public or private company?

key
Ownership
Public

How many people does Panbela Therapeutics employ?

people
Employees
7

What sector is Panbela Therapeutics in?

pie chart
Sector
Health Care

Where is the head office for Panbela Therapeutics?

location pin
Head Office
Minnesota, United States

What year was Panbela Therapeutics founded?

founded flag
Year Founded
2011
What does Panbela Therapeutics specialise in?
/Cancer Therapies /Drug Development /PDA-001 Drug /Clinical Trials /Scientific Research /Biopharmaceutical Company

What are the products and/or services of Panbela Therapeutics?

Overview of Panbela Therapeutics offerings
Developing Treatments for CNS Disorders: Panbela focuses on researching and developing medications for CNS disorders, including Parkinson's disease, levodopa-induced dyskinesia (LID), and Alzheimer's disease.
Utilizing Non-Dopaminergic Mechanisms: Their drug discovery efforts target non-dopaminergic mechanisms, aiming to address limitations associated with current therapies.
GBA1 Gene Mutations: One area of their research targets GBA1 gene mutations, a genetic risk factor for Parkinson's disease and other neurodegenerative disorders.
Pipeline of Drug Candidates: Panbela has a pipeline of drug candidates in various stages of development, including small molecules and gene therapies.
Pre-Clinical and Clinical Trials: Their drug candidates are currently undergoing pre-clinical and clinical trials to evaluate their safety and efficacy.
Focus on Improving Patient Outcomes: Overall, Panbela Therapeutics works to discover and develop medications that can improve patient outcomes for those suffering from CNS disorders.

Who is in the executive team of Panbela Therapeutics?

Panbela Therapeutics leadership team
  • Dr. Jennifer K. Simpson CRNP, M.S.N., Ph.D.
    Dr. Jennifer K. Simpson CRNP, M.S.N., Ph.D.
    CEO, President & Director
  • Ms. Susan  Horvath
    Ms. Susan Horvath
    VP of Finance, CFO, Secretary & Treasurer
  • Ms. Tammy  Groene
    Ms. Tammy Groene
    Vice President of Operations
  • Dr. Elizabeth  Bruckheimer Ph.D.
    Dr. Elizabeth Bruckheimer Ph.D.
    VP & Chief Scientific Officer